SGLT2 inhibitor for lupus nephritis with kidney disease
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests if an SGLT2 inhibitor can help protect kidney function in people who have lupus nephritis (kidney inflammation caused by lupus) and chronic kidney disease (CKD). The goal is to see if this medicine can slow down further kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with lupus nephritis (type III, IV, or V) through a kidney biopsy.
- Your kidney function is moderately reduced (eGFR between 15 and 60 mL/min).
- Your lupus is currently quiet or well-controlled, with no active kidney symptoms.
- You've been on a stable dose of prednisolone (5-7.5 mg daily) with or without MMF or AZA for the last 3 months.
- You do not have type 1 diabetes, frequent urinary tract infections, or a history of ketoacidosis.
- You are not on dialysis or have advanced kidney disease (stage 5 CKD).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called SGLT2 inhibitor (a type of diabetes drug that may also help protect the kidneys) in children with chronic kidney disease. It aims to see if the drug is safe and easy to use in children ages 2–18 with moderate to severe kidney problems.
This trial tests whether taking dapagliflozin (a drug often used for diabetes and heart health) can help improve kidney structure and blood flow in people who received a kidney transplant at least 9 months ago. It may benefit those whose kidney function is stable, regardless of whether they have diabetes.
This study tests if a diabetes drug called dapagliflozin can help people with active lupus nephritis by reducing protein in the urine and preserving kidney function. It is given in addition to standard treatments.
This trial tests if a type of diabetes medicine (SGLT-2 inhibitors) can reduce protein in the urine and protect kidney function in people with chronic kidney disease caused by lupus nephritis or ANCA-associated vasculitis. The medicine is already approved for other conditions, and researchers want to see if it works for these kidney diseases.
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.